JJ
APLM icon

Johnson & Johnson’s Apollomics APLM Stock Holding History

Johnson & Johnson’s Portfolio APLM Stock Details APLM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-133
Closed -$12.8K – 23
2023
Q4 		$12.8K Hold
133
– – ﹤0.01% 23
2023
Q3 		$49.6K Hold
133
– – 0.02% 21
2023
Q2 		$75.9K Hold
133
– – 0.02% 19
2023
Q1 		$321K Buy
+133
New +$356K 0.1% 18

Other funds holding APLM

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
ETC
Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return
PIA
Powell Investment Advisors Miami, Florida $290M AUM 21.61% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
B
Bensler Bellevue, Washington $1.13B AUM 38.91% 1-Year Est. Return
GKFF
George Kaiser Family Foundation Tulsa, Oklahoma $883M AUM 21.04% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Johnson & Johnson's APLM Position: Q1 2024 in Review

Johnson & Johnson sold out of Apollomics (APLM) in Q1 2024, closing a stake of 133 shares — an estimated $12.8K sold.

Johnson & Johnson first reported a position in APLM in Q1 2023 and held it in 4 quarters. The position peaked at $321K in Q1 2023. 12 funds tracked by Wall St. Rank hold APLM as of Q1 2024.

  • Johnson & Johnson reported no remaining Apollomics position as of Q1 2024 after selling out during the quarter.
  • Johnson & Johnson sold 133 Apollomics shares in Q1 2024, an estimated $12.8K.
  • Johnson & Johnson first reported a position in Apollomics in Q1 2023 and held it in 4 quarters.
  • Johnson & Johnson's Apollomics position peaked at $321K in Q1 2023.
  • 12 funds tracked by Wall St. Rank held Apollomics as of Q1 2024.

Based on Johnson & Johnson's 13F filing for Q1 2024, filed 10 May 2024.